Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nikki Adams

Nurse Practitioner Cookeville, TN Nurse Practitioner

NPI 1891778817 CMS profile 10885541

345 W Broad St, Cookeville, TN 38501

Open in the dashboard

General payments

$4,171

240 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nikki Adams of Cookeville, TN is reported in the CMS Open Payments database as having received $4,171 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $707 33
2024 General $1,082 61
2023 General $904 54
2022 General $777 48
2021 General $702 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nikki Adams
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Nikki Adams were reported at $707. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Nikki Adams Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $702 $135 $40–$426 $132
2022 $777 $152 $48–$470 $149
2023 $904 $166 $54–$529 $160
2024 $1,082 $173 $55–$556 $164
2025 $707 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $697 40 payments
  2. Lilly USA, LLC $486 31 payments
  3. AbbVie, Inc. $474 28 payments
  4. Pfizer Inc. $393 25 payments
  5. AstraZeneca Pharmaceuticals LP $234 15 payments
  6. Merck Sharp & Dohme Corporation $195 14 payments
  7. Amgen Inc. $187 10 payments
  8. Lundbeck LLC $174 6 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $165 9 payments
  10. Astellas Pharma US Inc $158 2 payments
  11. Other $1,009 60 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,171 240 payments
Products named General payments · program years 2021–2025
  1. Ozempic $471 27 payments
  2. RYBELSUS $387 26 payments
  3. NURTEC ODT Pain $376 23 payments
  4. MOUNJARO $370 23 payments
  5. UBRELVY $227 15 payments
  6. NURTEC ODT Primary Care $226 13 payments
  7. Wegovy $186 11 payments
  8. ELIQUIS $185 13 payments
  9. VYEPTI $174 6 payments
  10. BELSOMRA $167 12 payments
  11. Other $2,771 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$10,758

Of which drugs: $462

Medicare patients

207

Average age 75

Services billed

898

155 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 41%
Diabetes 25%
Ischemic heart disease 18%
Atrial fibrillation 10%
Cancer 10%
Depression 10%
COPD 9%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 69 300 $182
Injection, ceftriaxone sodium, per 250 mg J0696 Office 67 292 $74

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $135
$135 — —
VYEPTI
  • Lundbeck LLC $120
$120 — —
Wegovy
  • Novo Nordisk Inc $98
$98 — —
NURTEC ODT
  • PFIZER INC. $93
$93 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record